PEI first province to offer GARDASIL® to boys in school

Canadian parents support vaccinating boys in publicly funded programs 
B-roll available at: 
KIRKLAND, QC, April 18, 2013 /CNW Telbec/ - Today, Prince Edward Island became 
the first province in Canada to extend its publicly funded school-based HPV 
vaccination program to boys. The program will use GARDASIL(®) [Quadrivalent 
Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine], the only HPV 
vaccine indicated and recommended for boys and men. 
In 2007, The National Advisory Committee on Immunization (NACI) recommended 
the quadrivalent HPV vaccine to protect Canadian girls and women aged 9 to 26 
against a broad spectrum of HPV-related diseases. In 2012, NACI updated and 
strengthened its statement related to the use of HPV vaccines and recommended 
the use of the quadrivalent HPV vaccine in males between 9 to 26 years of 
"PEI was one of the first provinces to follow NACI's recommendations by 
introducing school-based HPV vaccination programs to girls in 2007. PEI's 
decision to include boys is an important milestone in protecting both males 
and females against the diseases that can result from HPV infection such as 
genital warts and anal-genital cancers," said Dr. Mauricio Ede, Medical 
Director, Medical Affairs at Merck Canada. "Both males and females contribute 
to the spread of HPV and both develop diseases as a result of HPV infection." 
More recently, The Canadian Medical Association adopted a resolution that 
calls for public funding to vaccinate both girls and boys for human 
A national survey conducted in March 2011 by Ipsos Reid(3), commissioned by 
Merck, showed that: 

    --  85% of parents of males would allow their son to get vaccinated
        against HPV if it was offered through a publicly-funded program
        at his school
    --  88% of parents support the assertion that boys should be
        vaccinated against HPV in the same program as girls
    --  91% of parents agree that vaccinating both boys and girls
        against HPV would provide greater protection than vaccinating
        girls alone

Australia, a country to which Canada is often compared, extended its national 
school-based HPV vaccination program to boys aged 12-13, earlier this year. It 
includes a catch-up program for 14 to 15 year-olds until the end of the 2014 
school year.(4)

About Merck
Today's Merck is a global healthcare leader working to help the world be 
well. Merck is known as MSD outside the United States and Canada. Through 
our medicines, vaccines, biologic therapies, and consumer and animal products, 
we work with customers and operate in more than 140 countries to deliver 
innovative health solutions. We also demonstrate our commitment to increasing 
access to healthcare through far-reaching policies, programs and partnerships. 
For more information about our operations in Canada, visit

Forward Looking Statement

This news release includes "forward-looking statements" within the meaning of 
the safe harbor provisions of the United States Private Securities Litigation 
Reform Act of 1995. These statements are based upon the current beliefs and 
expectations of Merck's management and are subject to significant risks and 
uncertainties. If underlying assumptions prove inaccurate or risks or 
uncertainties materialize, actual results may differ materially from those set 
forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry 
conditions and competition; general economic factors, including interest rate 
and currency exchange rate fluctuations; the impact of pharmaceutical industry 
regulation and health care legislation in the United States and 
internationally; global trends toward health care cost containment; 
technological advances, new products and patents attained by competitors; 
challenges inherent in new product development, including obtaining regulatory 
approval; Merck's ability to accurately predict future market conditions; 
manufacturing difficulties or delays; financial instability of international 
economies and sovereign risk; dependence on the effectiveness of Merck's 
patents and other protections for innovative products; and the exposure to 
litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking 
statement, whether as a result of new information, future events or otherwise. 
Additional factors that could cause results to differ materially from those 
described in the forward-looking statements can be found in Merck's 2011 
Annual Report on Form 10-K and the company's other filings with the Securities 
and Exchange Commission (SEC) available at the SEC's Internet site 

The news release is available at


(1) Public Health Agency of Canada Web site. Accessed at: 
(2 )The Canadian Medical Association Web site. Accessed at:
resolutions/2012GC-Resolutions_en.pdf. See pg 4 resolution 47. 
(3) Ipsos Reid factum issued on January 19, 2012. Accessed at:
(4) Australian Government, Department of Health and Ageing Web site. Available 

Media Contacts:

Sheila Murphy Merck 514-428-2748

Quebec Roch Landriault NATIONAL Public Relations 514-843-2345

Alberta Dan Brennan NATIONAL Public Relations 403-690-4556  

SOURCE: Merck Canada Inc.

To view this news release in HTML formatting, please use the following URL:

CO: CNW Enriched News Releases
ST: Prince Edward Island

-0- Apr/18/2013 18:21 GMT

Press spacebar to pause and continue. Press esc to stop.